About Isavuconazole News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from About isavuconazole. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In About Isavuconazole Today - Breaking & Trending Today

Basilea Pharmaceutica AG: Basileas Partner Asahi Kasei Pharma reicht Antrag auf Marktzulassung (NDA) von Isavuconazol in Japan ein

Ad hoc-Mitteilung gemäss Art. 53 KR Basel, 30. September 2021 Basilea Pharmaceutica AG (SIX: BSLN) gab heute bekannt, dass ihr Partner Asahi Kasei Pharma Corporation (Asahi Kasei Pharma) in Japan ....

United States , Sher Corporation , Services Or Achievements Of Basilea , S Partnership , Swiss Exchange , Market Approval , Hoc Notification , Fungal Infections , Milestone Payment , For Approval , Sales Markets , Tee Payment , Percent Range , Product Sales , End June , Prior Year Period , About Isavuconazole , Member States , Active Ingredient Orphan Drug Status , Latin America , Asia Pacific Space , Near East , North Africa , About Basilea , Cancer Or Infections , Drug Candidates ,

Basilea Pharmaceutica AG: Basierend auf positiven Phase-3-Ergebnissen bereitet Basileas Partner Asahi Kasei Pharma die Einreichung eines Antrags auf Marktzulassung (NDA) von Isavuconazol in Japan vor

Basilea Pharmaceutica AG: Basierend auf positiven Phase-3-Ergebnissen bereitet Basileas Partner Asahi Kasei Pharma die Einreichung eines Antrags auf Marktzulassung (NDA) von Isavuconazol in Japan vor
Basel, 26. Juli 2021
Basilea Pharmaceutica AG (SIX: BSLN) gab heute bekannt, dass ihr Partner Asahi Kasei Pharma Corporation (Asahi Kasei Pharma) beabsichtigt, auf Basis der positiven Ergebnisse der kürzlich abgeschlossenen Phase-3-Studie, in der Patienten mit tiefsitzenden Mykosen behandelt worden waren, für das Antimykotikum Isavuconazol (Cresemba
) einen Antrag auf Marktzulassung (New Drug Application, NDA) in Japan zu stellen. Asahi Kasei Pharma plant, Topline-Ergebnisse der Studie zu einem späteren Zeitpunkt zu veröffentlichen. ....

United States , July Basilea , Sher Corporation , Services Or Achievements Of Basilea , S Partnership , Basilea Press , Swiss Exchange , Request For , Market Approval , Hoc Notification , Japanese Patient , John Primary Endpoint , Treatment Side Effects , Fungal Infections , Years Running , For Approval , Isavuconazole Patient , New Sales Markets , Tee Payment , Percent Range , Product Sales , End March , Prior Year Period , About Isavuconazole , Member States , Active Ingredient Orphan Drug Status ,

Basilea Pharmaceutica AG: Basileas Partner Asahi Kasei Pharma schliesst Patientenrekrutierung in Phase-3-Studie mit Antimykotikum Isavuconazol (Cresemba) in Japan ab

Basilea Pharmaceutica AG: Basileas Partner Asahi Kasei Pharma schliesst Patientenrekrutierung in Phase-3-Studie mit Antimykotikum Isavuconazol (Cresemba) in Japan ab
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United States , Services Or Achievements Of Basilea , S Partnership , Development Of Medicines , Swiss Exchange , Basilea Corporation , Patient Recruitment , January Basilea , Japanese Patient , Market Opportunities , Study Results , Half Of The Year , Tee Payment , Percent Range , Product Sales , Prior Year Period , About Isavuconazole , Member States , Active Ingredient Orphan Drug Status , Latin America , Asia Pacific Space , Near East , North Africa , Fungal Infections , Immune System , Blood Cancer ,